The observed synergy between BCL2 family inhibitors and TKIs in eradicating CML-LSCs corroborates findings from previous studies and highlights a promising clinical strategy in improving medical cure in CML.8 The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.